NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$38.63
0.64 (1.68%)
▲
5d:
+6.89%
30d:
+8.6%
90d:
+39.91%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NGNE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NGNE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $38.63, which is considered extended relative to its 30-day fair value range of $34.18 to $37.67.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $30.57, while resistance sits at $40.16.
Market Sentiment: NGNE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.43 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $30.57, while resistance sits at $40.16.
Market Sentiment: NGNE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.43 (+108.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$34.18 -
$37.67
Company Quality Score
41/100
(HOLD)
Options IV Signal
14th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 14th percentile)
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 108.2% below Wall St target ($80.43)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$34.18 -
$37.67
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.89
(10.1%)
Support & Resistance Levels
Support Level
$30.57
Resistance Level
$40.16
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.46
Wall Street Target
$80.43
(+108.2%)
Share & Embed Analysis
Last updated: August 23, 2026 6:26 PM ET
Data refreshes hourly during market hours. Next update: 7:26 PM
Data refreshes hourly during market hours. Next update: 7:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
